Iranian Journal of Radiology

Published by: Kowsar

Endovascular Treatment with Drug-Coated Balloons in Femoropopliteal Artery Disease

Ibrahim Ilker Oz 1 , * , Muammer Bilici 2 , Namik Kemal Altinbas 3 , Evrim Bozay Oz 4 and Emrah Caglar 1
Authors Information
1 Department of Radiology, Bulent Ecevit University, School of Medicine, Zonguldak, Turkey
2 Department ofInternal Medicine, Bulent Ecevit University School of Medicine, Zonguldak, Turkey
3 Department of Radiology , Ankara University, School of Medicine, Ankara, Turkey
4 Department of Anesthesiology and Reanimation, Zonguldak State Hospital, Zonguldak, Turkey
Article information
  • Iranian Journal of Radiology: January 2018, 15 (1); e61841
  • Published Online: November 17, 2017
  • Article Type: Research Article
  • Received: July 4, 2016
  • Revised: February 15, 2017
  • Accepted: April 29, 2017
  • DOI: 10.5812/iranjradiol.61841

To Cite: Ilker Oz I, Bilici M, Kemal Altinbas N, Bozay Oz E, Caglar E. Endovascular Treatment with Drug-Coated Balloons in Femoropopliteal Artery Disease, Iran J Radiol. 2018 ; 15(1):e61841. doi: 10.5812/iranjradiol.61841.

Abstract
Copyright © 2017, Iranian Journal of Radiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
References
  • 1. Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. Catheter Cardiovasc Interv. 2015;86(4):611-25. doi: 10.1002/ccd.26122. [PubMed: 26256456].
  • 2. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015;373(2):145-53. doi: 10.1056/NEJMoa1406235. [PubMed: 26106946].
  • 3. Pentecost MJ, Criqui MH, Dorros G, Goldstone J, Johnston KW, Martin EC, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a Special Writing Group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. J Vasc Interv Radiol. 2003;14(9 Pt 2):S495-515. [PubMed: 14514865].
  • 4. Tsetis D, Uberoi R. Quality improvement guidelines for endovascular treatment of iliac artery occlusive disease. Cardiovasc Intervent Radiol. 2008;31(2):238-45. doi: 10.1007/s00270-007-9095-5. [PubMed: 18034277].
  • 5. Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res. 2015;116(9):1599-613. doi: 10.1161/CIRCRESAHA.116.303503. [PubMed: 25908731].
  • 6. Franzone A, Stabile E, Trimarco B, Esposito G. Peripheral drug-eluting technology. Cardiol Clin. 2015;33(1):151-62. doi: 10.1016/j.ccl.2014.09.005. [PubMed: 25439337].
  • 7. Banerjee S, Sarode K, Mohammad A, Brilakis ES. Drug-coated balloon and stent therapies for endovascular treatment of atherosclerotic superficial femoral artery disease. Curr Cardiol Rep. 2015;17(5):36. doi: 10.1007/s11886-015-0586-8. [PubMed: 25894799].
  • 8. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655-64. doi: 10.1016/S0140-6736(15)60657-2. [PubMed: 26334160].
  • 9. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wohrle J, Jeger R, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013;102(11):785-97. doi: 10.1007/s00392-013-0609-7. [PubMed: 23982467].
  • 10. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. [PubMed: 18779447].
  • 11. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689-99. doi: 10.1056/NEJMoa0706356. [PubMed: 18272892].
  • 12. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831-40. doi: 10.1161/CIRCINTERVENTIONS.112.971630. [PubMed: 23192918].
  • 13. Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012;19(5):571-80. doi: 10.1583/JEVT-12-3926MR.1. [PubMed: 23046320].
  • 14. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022. [PubMed: 24456716].
  • 15. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495-502. doi: 10.1161/CIRCULATIONAHA.114.011004. [PubMed: 25472980].
  • 16. van Overhagen H, Spiliopoulos S, Tsetis D. Below-the-knee interventions. Cardiovasc Intervent Radiol. 2013;36(2):302-11. doi: 10.1007/s00270-013-0550-1. [PubMed: 23354963].
  • 17. Perez de Prado A, Perez-Martinez C, Cuellas Ramon C, Regueiro Purrinos M, Diego Nieto A, Gonzalo-Orden JM, et al. Safety and efficacy of different paclitaxel-eluting balloons in a porcine model. Rev Esp Cardiol (Engl Ed). 2014;67(6):456-62. doi: 10.1016/j.rec.2013.09.030. [PubMed: 24863594].
  • 18. Ferraresi R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, et al. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg. 2009;37(3):336-42. doi: 10.1016/j.ejvs.2008.12.001. [PubMed: 19112033].
  • 19. Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability. J Endovasc Ther. 2016;23(2):356-70. doi: 10.1177/1526602815626557. [PubMed: 26823485].
  • 20. Heilmann T, Richter C, Noack H, Post S, Mahnkopf D, Mittag A, et al. Drug release profiles of different drug-coated balloon platforms. Eur Cardiol. 2010;6(4):40-4.
  • 21. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921-9. doi: 10.1016/j.jacc.2005.09.065. [PubMed: 16516072].
  • 22. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb. 1998;5(1):29-35. [PubMed: 10077455].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments